BR9914096A - Forma de dosagem oral, distinta, método para prevenir ou tratar distúrbio hipercinético de déficit de atenção ou depressão, uso de uma forma de dosagem oral distinta, e, método para tratar vìcio de produtos contendo nicotina - Google Patents
Forma de dosagem oral, distinta, método para prevenir ou tratar distúrbio hipercinético de déficit de atenção ou depressão, uso de uma forma de dosagem oral distinta, e, método para tratar vìcio de produtos contendo nicotinaInfo
- Publication number
- BR9914096A BR9914096A BR9914096-9A BR9914096A BR9914096A BR 9914096 A BR9914096 A BR 9914096A BR 9914096 A BR9914096 A BR 9914096A BR 9914096 A BR9914096 A BR 9914096A
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- oral dosage
- treat
- different oral
- depression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10211298P | 1998-09-28 | 1998-09-28 | |
| PCT/EP1999/007117 WO2000018406A1 (en) | 1998-09-28 | 1999-09-24 | Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9914096A true BR9914096A (pt) | 2001-07-31 |
Family
ID=22288187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9914096-9A BR9914096A (pt) | 1998-09-28 | 1999-09-24 | Forma de dosagem oral, distinta, método para prevenir ou tratar distúrbio hipercinético de déficit de atenção ou depressão, uso de uma forma de dosagem oral distinta, e, método para tratar vìcio de produtos contendo nicotina |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1117407A1 (ja) |
| JP (1) | JP2002525328A (ja) |
| KR (1) | KR20010075385A (ja) |
| CN (1) | CN1328459A (ja) |
| AR (1) | AR022673A1 (ja) |
| AU (1) | AU6087399A (ja) |
| BR (1) | BR9914096A (ja) |
| CA (1) | CA2345638A1 (ja) |
| CZ (1) | CZ20011142A3 (ja) |
| HU (1) | HUP0103459A2 (ja) |
| IL (1) | IL142054A0 (ja) |
| MA (1) | MA26693A1 (ja) |
| NO (1) | NO20011555L (ja) |
| PE (1) | PE20001087A1 (ja) |
| PL (1) | PL346877A1 (ja) |
| TR (1) | TR200100863T2 (ja) |
| WO (1) | WO2000018406A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001026641A2 (en) * | 1999-10-13 | 2001-04-19 | Glaxo Group Limited | Morpholinol derivatives for the treatment of obesity |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4597969A (en) * | 1982-04-05 | 1986-07-01 | Merck Sharp & Dohme | Stabilization of unstable drugs or food supplements |
| GB8924528D0 (en) * | 1989-10-31 | 1989-12-20 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
-
1999
- 1999-09-23 MA MA25782A patent/MA26693A1/fr unknown
- 1999-09-24 PL PL99346877A patent/PL346877A1/xx unknown
- 1999-09-24 BR BR9914096-9A patent/BR9914096A/pt not_active IP Right Cessation
- 1999-09-24 AR ARP990104841A patent/AR022673A1/es unknown
- 1999-09-24 KR KR1020017003874A patent/KR20010075385A/ko not_active Application Discontinuation
- 1999-09-24 CA CA002345638A patent/CA2345638A1/en not_active Abandoned
- 1999-09-24 AU AU60873/99A patent/AU6087399A/en not_active Abandoned
- 1999-09-24 EP EP99947420A patent/EP1117407A1/en not_active Withdrawn
- 1999-09-24 JP JP2000571924A patent/JP2002525328A/ja active Pending
- 1999-09-24 CZ CZ20011142A patent/CZ20011142A3/cs unknown
- 1999-09-24 TR TR2001/00863T patent/TR200100863T2/xx unknown
- 1999-09-24 IL IL14205499A patent/IL142054A0/xx unknown
- 1999-09-24 HU HU0103459A patent/HUP0103459A2/hu unknown
- 1999-09-24 CN CN99813675A patent/CN1328459A/zh active Pending
- 1999-09-24 WO PCT/EP1999/007117 patent/WO2000018406A1/en not_active Application Discontinuation
- 1999-09-27 PE PE1999000976A patent/PE20001087A1/es not_active Application Discontinuation
-
2001
- 2001-03-27 NO NO20011555A patent/NO20011555L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20011555D0 (no) | 2001-03-27 |
| TR200100863T2 (tr) | 2001-07-23 |
| WO2000018406A1 (en) | 2000-04-06 |
| AU6087399A (en) | 2000-04-17 |
| CZ20011142A3 (cs) | 2001-09-12 |
| EP1117407A1 (en) | 2001-07-25 |
| CA2345638A1 (en) | 2000-04-06 |
| PL346877A1 (en) | 2002-03-11 |
| IL142054A0 (en) | 2002-03-10 |
| PE20001087A1 (es) | 2000-10-20 |
| JP2002525328A (ja) | 2002-08-13 |
| KR20010075385A (ko) | 2001-08-09 |
| AR022673A1 (es) | 2002-09-04 |
| MA26693A1 (fr) | 2004-12-20 |
| HUP0103459A2 (hu) | 2002-01-28 |
| CN1328459A (zh) | 2001-12-26 |
| NO20011555L (no) | 2001-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE390135T1 (de) | Verfahren zur verwendung von und zusammensetzungen mit immunomodulatorischen verbindungen zur behandlung und versorgung von myelodysplastischen syndromen | |
| AR050418A1 (es) | Dosificacion fija de anticuerpos her | |
| MXPA05013637A (es) | Inhibidores gsk-3 y usos de los mismos. | |
| MY141584A (en) | Pharmaceutical uses of bisphosphonates | |
| CY1109146T1 (el) | Υγρο φαρμακευτικο σκευασμα που περιλαμβανει νικοτινη για τη χορηγηση στην στοματικη κοιλοτητα | |
| PL1654253T3 (pl) | Podstawione pochodne 3-pirolidynoindolu | |
| MX2007005065A (es) | Forma de dosis de tiempo de retraso de farmacos para la terapia de insomnio. | |
| MXPA05009103A (es) | Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios. | |
| ATE322265T1 (de) | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält | |
| DE60027575D1 (de) | Verwendung von Spinosad oder einer Zusammensetzung enthaltend spinosad | |
| CO5640120A2 (es) | Formulacion y metodods para el tratamiento de trombocitemia | |
| ATE146677T1 (de) | Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| IL151628A0 (en) | Combination therapies with vascular damaging activity | |
| WO2001080837A3 (de) | Transdermale oder transmucosale darreichungsformen mit einer nicotinhaltigen wirkstoffkombination zur raucherentwöhnung | |
| TW200509992A (en) | Dosage form containing pantoprazole as active ingredient | |
| AR022621A1 (es) | Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina | |
| TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
| BR9914096A (pt) | Forma de dosagem oral, distinta, método para prevenir ou tratar distúrbio hipercinético de déficit de atenção ou depressão, uso de uma forma de dosagem oral distinta, e, método para tratar vìcio de produtos contendo nicotina | |
| MXPA06007007A (es) | Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores. | |
| MXPA04004907A (es) | Composiciones de acetaminofen. | |
| EP1603595A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DRUG INDEPENDENCE | |
| WO2008060535A3 (en) | Use of reversine and analogs for treatment of cancer | |
| WO2006041769A3 (en) | Methods for the treatment of substance abuse and addiction | |
| PL1668021T3 (pl) | Nowe związki tioksylozy, sposób ich przygotowania, zawierające je kompozycje farmaceutyczne i ich zastosowanie w lecznictwie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007. |